RxDoctor Payments Data

Brett Twente, MD

Internal Medicine · Milwaukee, WINPI 1194784629

Payments from drug & device makers

$664in general payments, 2019–2025

Across 15 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$142
  • AstraZeneca$137
  • Johnson & Johnson$128
  • Novartis$73
  • Abbott$50
  • Bayer$36
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$61492%
  • Education$508%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$52,495
Medicare patients
240
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide213$285,875
EliquisApixaban249$242,534
JardianceEmpagliflozin125$127,489
XareltoRivaroxaban81$71,362
OzempicSemaglutide36$56,452
JanuviaSitagliptin Phosphate43$43,561
MounjaroTirzepatide31$35,721
Spiriva HandihalerTiotropium Bromide49$33,157
LinzessLinaclotide23$14,419
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$14,343
Atorvastatin Calcium1,230$13,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$12,977
SymbicortBudesonide/Formoterol Fumarate28$9,431
Breo ElliptaFluticasone/Vilanterol15$9,409
Spiriva RespimatTiotropium Bromide15$7,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$128$71,36281 claims
Novo NordiskOzempic$142$56,45236 claims
GSKBreo Ellipta, Incruse Ellipta$25$15,79229 claims
AstraZenecaSymbicort$137$9,43128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →